Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females
Phase 1
Completed
- Conditions
- Headache, Migraine
- Interventions
- Drug: Ethynil Estradiol/Norgestimate Oral Contraceptive
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 41
- Registration Number
- NCT02792517
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study
Completed
- Conditions
- RAS Wild Type mCRC
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 238
- Registration Number
- NCT02792478
- Locations
- 🇪🇸
Research Site, Murcia, Spain
A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2019-10-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT02791516
- Locations
- 🇰🇷
Research Site, Suwon-si, Gyeonggi-do, Korea, Republic of
A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases
Phase 1
Completed
- Conditions
- Dermatomyositis, Polymyositis, Sjogren's, SLE, SSc
- Interventions
- Biological: Placebo
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT02780674
- Locations
- 🇺🇸
Research Site, Duncansville, Pennsylvania, United States
A Phase 1b Study of MEDI4920 in Participants With Adult-onset Rheumatoid Arthritis
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 57
- Registration Number
- NCT02780388
- Locations
- 🇵🇱
Research Site, Warszawa, Poland
A Study to Evaluate the Pharmacokinetic Exposure of 2 Formulations of Apremilast in Healthy Adults
- First Posted Date
- 2016-05-19
- Last Posted Date
- 2021-07-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 144
- Registration Number
- NCT02777554
- Locations
- 🇺🇸
Covance-Daytona Beach, Daytona Beach, Florida, United States
🇺🇸Covance Clinical Research Unit Inc, Madison, Wisconsin, United States
Chart Review of Repatha® in Subjects With Hyperlipidaemia
Completed
- Conditions
- Hypercholesterolaemia
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1986
- Registration Number
- NCT02770131
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 15
- Registration Number
- NCT02756845
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Marseille - Hopital de la Timone, Marseille cedex 5, France
🇺🇸AI Dupont Hospital for Children, Wilmington, Delaware, United States
🇫🇷Institut Hematologie et Oncologie Pediatrique, Lyon cedex 08, France
Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast
- First Posted Date
- 2016-04-25
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 80
- Registration Number
- NCT02749370
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
Phase 3
Completed
- Conditions
- Type 2 DiabetesHypercholesterolemiaMixed Dyslipidemia
- Interventions
- Drug: Placebo to EvolocumabBiological: Evolocumab
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 424
- Registration Number
- NCT02739984
- Locations
- 🇪🇸
Research Site, Barcelona, Cataluña, Spain
© Copyright 2025. All Rights Reserved by MedPath